文献速递神经肿瘤

基于DNA甲基化的脑膜瘤复发预测模型的验证与新一代更新:一项多中心前瞻性研究

Validation and next-generation update of a DNA methylation-based recurrence predictor for meningioma: A multicenter prospective study.
PubMed 文献 · Neuro Oncol · 2025-01-01

本研究利用1347例脑膜瘤病例(含3家机构469例前瞻性病例及100例WHO 2级外部验证队列)验证基于DNA甲基化的复发预测模型,并推出适配新一代甲基化芯片的简化预测器。原模型与新一代模型预测术后早期复发的性能均显著优于2021 WHO分级,风险分层在WHO 1级和2级内均有预测价值(P < .05),多变量Cox回归显示辅助放疗在高风险病例中获益。

要点

  • 新一代DNA甲基化预测器在预测复发时间上显著优于2021 WHO分级。
  • 风险分层在WHO 1级和2级肿瘤内均可预测结局(P < .05),WHO 3级均视为高风险。
  • 多变量Cox回归显示辅助放疗在高风险病例中获益,支持其用于临床决策。

核心结论

  • 新一代基于DNA甲基化的脑膜瘤结局预测器在预测复发时间上显著优于2021 WHO分级。
  • 该工具以点击式工具形式提供,将改善预后判断、辅助放疗患者选择并支持分子分层临床试验。

研究设计与样本

  • 研究为多中心前瞻性验证,使用Illumina EPICArray生成全基因组甲基化谱。
  • 共纳入1347例脑膜瘤病例,包括来自3家机构的469例前瞻性病例和100例WHO 2级外部验证队列。
  • 采用时间依赖受试者工作特征曲线比较新一代预测器、原模型与2021 WHO分级的性能。
  • 将甲基化预测器与WHO分级及切除范围整合生成列线图。

主要发现

  • 原模型与新一代模型在预测术后早期复发方面均显著优于2021 WHO分级。
  • 将患者二分为各级别特异性风险亚组,在WHO 1级和2级肿瘤内均可预测结局(P < .05),而所有WHO 3级肿瘤均被视为高风险。
  • 多变量Cox回归显示辅助放疗在高风险病例中获益。
  • 新一代预测器所含特征数较原模型减少近10倍,允许采用靶向芯片。

临床怎么用

  • 作者指出该预测器以点击式工具提供,可改善预后判断、辅助放疗患者选择并支持分子分层临床试验。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We previously developed a DNA methylation-based risk predictor for meningioma, which has been used locally in a prospective fashion since its original publication. As a follow-up, we validate this model using a large prospective cohort and introduce a streamlined next-generation predictor compatible with newer methylation arrays. METHODS: Genome-wide methylation profiles were generated with the Illumina EPICArray. The performance of our next-generation predictor was compared with our original model and standard-of-care 2021 WHO grade using time-dependent receiver operating characteristic curves. An nomogram was generated by incorporating our methylation predictor with WHO grade and the extent of resection. RESULTS: A total of 1347 meningioma cases were utilized in the study, including 469 prospective cases from 3 institutions and an external cohort of 100 WHO grade 2 cases for model validation. Both the original and next-generation models significantly outperform the 2021 WHO grade in predicting early postoperative recurrence. Dichotomizing patients into grade-specific risk subgroups was predictive of outcomes within both WHO grades 1 and 2 tumors (P < .05), whereas all WHO grade 3 tumors were considered high-risk. Multivariable Cox regression demonstrated the benefit of adjuvant radiotherapy (RT) in high-risk cases specifically, reinforcing its informative role in clinical decision-making. Finally, our next-generation predictor contains nearly 10-fold fewer features than the original model, allowing for targeted arrays. CONCLUSIONS: This next-generation DNA methylation-based meningioma outcome predictor significantly outperforms the 2021 WHO grading in predicting time to recurrence. We make this available as a point-and-click tool that will improve prognostication, inform patient selection for RT, and allow for molecularly stratified clinical trials.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Landry AP, Wang JZ, Patil V, et al. Validation and next-generation update of a DNA methylation-based recurrence predictor for meningioma: A multicenter prospective study. Neuro Oncol. 2025. PMID: 39503370. doi:10.1093/neuonc/noae236

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。